Mutations in *DRP2* (OMIM \#300052) encoding dystrophin-related protein 2, a 957 amino acid protein, were identified in a single patient with X-linked Charcot-Marie-Tooth (CMT) disease and are associated with familial autism.^[@R1],[@R2]^ *DRP2* is predominantly expressed in the brain and spinal cord and functionally interacts with periaxin (*PRX*, OMIM \#605725), a known causative CMT gene (OMIM \#614895 and \#145900), in the PRX-DRP2-dystroglycan (PDG) complex.^[@R3]^ The PDG complex supports and maintains Cajal bands, which are cytoplasmic extensions that run along the length of myelinated axons and are required for establishing a proper internodal length.^[@R4][@R5][@R6]^

A nonsense *DRP2* c.805C\>T (Q269X) mutation was found in a patient with sensorimotor neuropathy, with intermediate conduction velocities and absence of Cajal bands within dermal nerves.^[@R1]^ Here, we report another patient with a novel nonsense mutation in *DRP2* with sensorimotor polyneuropathy and histologic myelin abnormalities. This report extends the known mutation spectrum of *DRP2* and provides further evidence of its association with inherited neuropathy.

Case report {#s1}
===========

The index patient is a 42-year-old man who developed fatigue, numbness and tingling in his fingers and toes, and headaches at the age of 18. Over time, he developed patchy burning in his extremities, intermittent numbness in his face, heat intolerance, and excessive sweating. There was no family history of neuropathy. Nerve conduction studies at the age of 33 demonstrated mildly slowed conduction velocities and prolonged F-wave latencies in the lower extremities. A left sural nerve biopsy showed fibers with tomaculae, thinly myelinated fibers, and a small focus of perivascular epineurial inflammation. A lumbar puncture was performed and showed normal CSF protein levels and cell counts. Testing for diabetes mellitus, Sjogren syndrome, HIV, and Lyme disease was negative, and hexosaminidase A and α-galactosidase levels were normal. Testing for mutations of *PMP22*, *MFN2*, and *GBJ1* was negative.

At the age of 40, examination showed normal cognition, cranial nerves, muscle bulk, tone, and strength. He was able to walk on his heels and toes. Deep tendon reflexes were mildly reduced at the ankles (1+) but were otherwise normal. There was multimodal distal sensory loss with light touch, pinprick, and temperature reduced in the lower extremities to the mid-shins and in the upper extremities to the mid-forearms. Joint position sense was preserved, and vibration sense was normal except for a mild reduction at the left first toe. Augmented Romberg (feet in tandem position) was positive. Repeat electrophysiology revealed evidence of lower extremity demyelinating neuropathy with nonuniformly reduced conduction velocities of the bilateral peroneal motor nerves (right 31 m/s, left 22 m/s, normal ≥40 m/s) with normal distal latencies, partial motor conduction block in the bilateral peroneal motor nerves recorded at the extensor digitorum brevis muscle (\[ankle vs fibular head stimulation\]: right \[2.5 vs 0.9 mV\], left \[1.5 vs 0.1 mV\]), and markedly prolonged lower extremity F-wave latencies (right tibial 82 milliseconds, left peroneal 73 milliseconds, normal \<56 milliseconds). Upper extremity testing showed a normal conduction velocity in the median motor nerve and a slightly reduced velocity (46 m/s, normal ≥50 m/s) in the ulnar motor nerve. Skin biopsy and autonomic testing were normal.

Electron microscopy of his sural nerve revealed a mild reduction in the density of large myelinated and unmyelinated axons as well as prominent variability in myelin thickness with many thinly myelinated fibers and some abnormally thick myelinated fibers ([figure](#F1){ref-type="fig"}). We observed many fibers with delamination of myelin, occasional Cajal bands, rare tomaculae, rare active demyelination, and rare miniature onion bulbs indicative of prior demyelination and attempted remyelination. Whole-exome sequencing revealed a hemizygous c.1039C\>T, p.Q347X variant in *DRP2* that creates a premature stop codon. This variant is not present in the database of the Exome Aggregation Consortium ([exac.broadinstitute.org](http://exac.broadinstitute.org), September 2016). His unaffected mother is a carrier for the change.

![Sural nerve electron microscopy\
(A and B) Sural nerve biopsy shows variability in myelin thickness, with some fibers exhibiting thicker myelin sheets relative to axon diameter (thin arrows) and many others harboring thin myelin (thick arrowheads). Many of the thicker myelinated fibers showed delamination. (C and D) Higher power view of myelin thickness variability. Thickly myelinated axon (thin arrow) shows a small tomacula. (E) Miniature onion bulb formation. (F) A myelinated axon (thin arrow) undergoing demyelination. Scale bars denote 10 μm in A and B, 5 μm in C and D, and 2 μm in E and F.](NG2017006346FF1){#F1}

Discussion {#s2}
==========

In this report, we present a patient with early adult-onset sensorimotor neuropathy with biopsy-proven myelination abnormalities and a likely pathogenic hemizygous mutation in the X-linked gene *DRP2*. This mutation produces a premature stop codon and is expected to lead to a loss of functional protein and likely a complete absence of DRP2 in men.^[@R1],[@R7]^ The biopsy findings are reminiscent of the previously reported patient with *DRP2* mutation who displayed the absence of Cajal bands in dermal nerves, and to the histologic features of *Drp2*-null mice, which show disrupted appositions of Cajal bands, focal hypermyelination, demyelination, and tomacula-like formations.^[@R1],[@R8]^ Similarly, *Prx*-null mice also show the absence of Cajal bands, shortened internodal length, and reduced conduction velocities.^[@R9]^ It is important that the patient reported here had features of both developmental dysmyelination as well as nonuniform demyelination, the latter of which was not present in the previously reported patient with *DRP2* mutation. This report provides further evidence linking truncating *DRP2* mutations with demyelinating neuropathy and suggests that *DRP2* variants should be considered when evaluating patients suspected of inherited neuropathy.

Author contributions
====================

Dr. Roda: drafting and revision of the manuscript and analysis of patient data. Dr. McCray: critical analysis and revision of the manuscript. Dr. Klein: patient care and critical analysis and revision of the manuscript. Dr. Hoke: patient care, electron microscopy, and critical analysis and revision of the manuscript.

Study funding
=============

No targeted funding reported.

Disclosure
==========

R. Roda and McCray have received research support from the NIH. B. C. Klein serves on the CMTA Research and Therapeutics board (a nonprofit patient support group); serves on the editorial board of *Neurology*®; and receives research support from a Mayo Clinic research grant. Dr. Hoke serves on the scientific advisory board of the Foundation for Peripheral Neuropathy; serves on the editorial boards of *Experimental Neurology* and *Annals of Clinical Translational Neurology*; holds patents for Use of ethoxyquin to prevent neuropathy and for Electro-spun fiber mesh to help nerve regeneration; is an employee of Johns Hopkins University; has served as a consultant for Neurocrine Inc.; has received research support from the NIH, the Foundation for Peripheral Neuropathy, and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; gave expert testimony on GBS for National Vaccine Injury Program, and gave expert testimony on peripheral neuropathy for Arnold & Porter Kaye Scholer LLP. Full disclosure form information provided by the authors is available with the full text of this article at [Neurology.org/NG](http://ng.neurology.org/lookup/doi/10.1212/NXG.0000000000000220).

[^1]: Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at [Neurology.org/NG](http://ng.neurology.org/lookup/doi/10.1212/NXG.0000000000000220).

[^2]: The Article Processing Charge was funded by the authors.
